Clinical longitudinal standards for height and height velocity for North American children

Tanner, J. M.; Davies, P. L.

doi:10.1016/s0022-3476(85)80501-1

Cited by 990 publications

(568 citation statements)

References 18 publications

Supporting

Mentioning

487

Contrasting

Unclassified

Order By: Relevance

“…In this study, only patients with initial cephalometric radiographs recorded at a minimum age of 15 years were included. By this age, circumpubertal growth is complete or almost complete, 9 and so the possible confounding effects of facial growth in the analysis were minimized. There was also no evidence that growth assisted improvement because analysis confirmed that patient age at the start of treatment did not influence treatment outcome.…”

Section: Discussionmentioning

confidence: 99%

A cephalometric study of Class II malocclusions treated with mandibular surgery

Burden

Johnston

Kennedy³

et al. 2007

American Journal of Orthodontics and Dentofacial Orthopedics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

A cephalometric study of Class II malocclusions treated with mandibular surgery

Burden

Johnston

Kennedy³

et al. 2007

American Journal of Orthodontics and Dentofacial Orthopedics

View full text Add to dashboard Cite

“…of height for persons of the same sex and age. 15 A similar formula was used to calculate weight z scores. The day of granulocyte engraftment was defined as the first of 3 consecutive days in which the patient's absolute granulocyte count exceeded 500/mm 3 .…”

Section: Discussionmentioning

confidence: 99%

Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome

Leung

Pitts

Burnette

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The objective of this study is to investigate the outcome of children 24 months of age or younger (infants) at the time of allogeneic bone marrow transplantation (BMT) for acute leukemia or myelodysplasia. We analyzed the survival rate, prognostic factors, incidences of late sequelae, and immune reconstitution in 22 infants who underwent allogeneic BMT. The 5-year event-free survival estimate was 45.5% (95% confidence interval (CI), 24.4% to 63.3%). Six patients died of transplant-related complications and six died of disease relapse. Remission status at the time of BMT was the most important prognostic factor (P ‫؍‬ 0.005): no patient who received a transplant while their disease was not in remission survived, whereas the 5-year survival estimate for infants who underwent BMT during remission was 56% (95% CI, 31% to 75%). Long-term outcomes in the 10 infant survivors were compared with those of 10 older controls matched for diagnosis, disease status at the time of BMT, calendar year at the time of BMT, and source of stem cells. Immune function 1 year after transplantation and the incidences and spectra of late sequelae were similar for both groups during a median of 3.5 years (range, 1.5 to 7.2 years) of follow-up. Bone Marrow Transplantation (2001) 27, 717-722. Keywords: allogeneic transplantation; infant leukemia; myelodysplastic syndrome; late sequelaeThe incidences of lymphoid and myeloid leukemias in infants are approximately equal. Acute lymphoblastic leukemia (ALL) in infants accounts for 2.5% to 5% of all cases of childhood ALL, and acute myeloid leukemia (AML) in infants accounts for 6% to 14% of all cases of childhood AML. 1 The frequent presence of poor prognostic factors such as 11q23/MLL rearrangement in ALL and a high leukocyte count at the time of diagnosis of AML results in an overall long-term survival of only approxiCorrespondence: WH Leung,

show abstract

“…for age 18 were assessed for GH deficiency using the clonidine and arginine stimulation tests. 19,20 Peak values of plasma GH levels below 10 ng/ml on both tests were considered indicative of GH deficiency.…”

Section: Methodsmentioning

confidence: 99%

Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation

Chemaitilly

Boulad

Heller

et al. 2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Impaired linear growth has been shown to occur in individuals treated during childhood with single-dose and fractionated total body irradiation (TBI) before stem cell transplantation. Our objective was to describe the final heights attained and patient/treatment factors correlating with final height in a cohort of childhood cancer survivors treated with hyperfractionated TBI (total dose 1375 or 1500 cGy). Thirty individuals (18 men In conclusion, treatment with hyperfractionated TBI is associated with a reduction in standing height and an even greater reduction in sitting height. Final height after hyperfractionated TBI was similar to that reported after fractionated TBI.

show abstract

Clinical longitudinal standards for height and height velocity for North American children

Cited by 990 publications

References 18 publications

A cephalometric study of Class II malocclusions treated with mandibular surgery

A cephalometric study of Class II malocclusions treated with mandibular surgery

Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome

Final height in pediatric patients after hyperfractionated total body irradiation and stem cell transplantation

Contact Info

Product

Resources

About